Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 5/2014

Open Access 01-10-2014 | Review

Antibiotic stewardship in the intensive care unit

Authors: Charles-Edouard Luyt, Nicolas Bréchot, Jean-Louis Trouillet, Jean Chastre

Published in: Critical Care | Issue 5/2014

Login to get access

Abstract

The rapid emergence and dissemination of antimicrobial-resistant microorganisms in ICUs worldwide constitute a problem of crisis dimensions. The root causes of this problem are multifactorial, but the core issues are clear. The emergence of antibiotic resistance is highly correlated with selective pressure resulting from inappropriate use of these drugs. Appropriate antibiotic stewardship in ICUs includes not only rapid identification and optimal treatment of bacterial infections in these critically ill patients, based on pharmacokinetic-pharmacodynamic characteristics, but also improving our ability to avoid administering unnecessary broad-spectrum antibiotics, shortening the duration of their administration, and reducing the numbers of patients receiving undue antibiotic therapy. Either we will be able to implement such a policy or we and our patients will face an uncontrollable surge of very difficult-to-treat pathogens.
Appendix
Available only for authorised users
Literature
1.
Arnold HM, Micek ST, Skrupky LP, Kollef MH: Antibiotic stewardship in the intensive care unit. Semin Respir Crit Care Med. 2011, 32: 215-227.
2.
Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O: Antibiotic resistance - the need for global solutions. Lancet Infect Dis. 2013, 13: 1057-1098.
3.
Leuthner KD, Doern GV: Antimicrobial stewardship programs. J Clin Microbiol. 2013, 51: 3916-3920.
4.
Bergmans DC, Bonten MJ, Gaillard CA, van Tiel FH, van der Geest S, de Leeuw PW, Stobberingh EE: Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother. 1997, 39: 527-535.
5.
Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J: DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis. 2014, 58: 1072-1083.
6.
Kollef MH: Optimizing antibiotic therapy in the intensive care unit setting. Crit Care. 2001, 5: 189-195.
7.
Kollef MH, Fraser VJ: Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001, 134: 298-314.
8.
McGowan JE: Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis. 1983, 5: 1033-1048.
9.
Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, Schlosser J, Martone WJ: Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals, A challenge to hospital leadership. JAMA. 1996, 275: 234-240.
10.
Lipsitch M, Bergstrom CT, Levin BR: The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci U S A. 2000, 97: 1938-1943.
11.
MacDougall C, Polk RE: Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. 2005, 18: 638-656.
12.
Paterson DL: The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis. 2006, 42: S90-S95.
13.
Rice LB: The maxwell finland lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. Clin Infect Dis. 2008, 46: 491-496.
14.
Shlaes DM, Gerding DN, John JF, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C: Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997, 25: 584-599.
15.
Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S: Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013, 34: 1-14.
16.
Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ: Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998, 42: 521-527.
17.
Zillich AJ, Sutherland JM, Wilson SJ, Diekema DJ, Ernst EJ, Vaughn TE, Doebbeling BN: Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. Infect Control Hosp Epidemiol. 2006, 27: 1088-1095.
18.
Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plesiat P, Andremont A: Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013, 57: 1488-1495.
19.
Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H: Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007, 369: 482-490.
20.
Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, Flores C, Brooks S: Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med. 2002, 162: 1515-1520.
21.
Kollef MH: Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000, 31: S131-S138.
22.
Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999, 115: 462-474.
23.
Kumar A: Early antimicrobial therapy in severe sepsis and septic shock. Curr Infect Dis Rep. 2010, 12: 336-344.
24.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006, 34: 1589-1596.
25.
Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Dodek P, Kravetsky L, Doucette S: Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010, 38: 1773-1785.
26.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013, 41: 580-637.
27.
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.Am J Respir Crit Care Med 2005, 171:388–416.,
28.
Masterton RG, Galloway A, French G, Street M, Armstrong J, Brown E, Cleverley J, Dilworth P, Fry C, Gascoigne AD, Knox A, Nathwani D, Spencer R, Wilcox M: Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2008, 62: 5-34.
29.
Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D: Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care. 2008, 23: 138-147.
30.
Amaral AC, Holder MW: Timing of antimicrobial therapy after identification of ventilator-associated condition is not associated with mortality in patients with ventilator-associated pneumonia: a cohort study. PLoS One. 2014, 9: e97575-
31.
Bloos F, Thomas-Ruddel D, Ruddel H, Engel C, Schwarzkopf D, Marshall JC, Harbarth S, Simon P, Riessen R, Keh D, Dey K, Weiss M, Toussaint S, Schadler D, Weyland A, Ragaller M, Schwarzkopf K, Eiche J, Kuhnle G, Hoyer H, Hartog C, Kaisers U, Reinhart K: Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study. Crit Care. 2014, 18: R42-
32.
Hranjec T, Rosenberger LH, Swenson B, Metzger R, Flohr TR, Politano AD, Riccio LM, Popovsky KA, Sawyer RG: Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis. 2012, 12: 774-780.
33.
Pines JM, Isserman JA, Hinfey PB: The measurement of time to first antibiotic dose for pneumonia in the emergency department: a white paper and position statement prepared for the American Academy of Emergency Medicine. J Emerg Med. 2009, 37: 335-340.
34.
Quattromani E, Powell ES, Khare RK, Cheema N, Sauser K, Periyanayagam U, Pirotte MJ, Feinglass J, Mark Courtney D: Hospital-reported data on the pneumonia quality measure ‘Time to first antibiotic dose’ are not associated with inpatient mortality: results of a nationwide cross-sectional analysis. Acad Emerg Med. 2011, 18: 496-503.
35.
Welker JA, Huston M, McCue JD: Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med. 2008, 168: 351-356.
36.
Yahav D, Leibovici L, Goldberg E, Bishara J, Paul M: Time to first antibiotic dose for patients hospitalised with community-acquired pneumonia. Int J Antimicrob Agents. 2013, 41: 410-413.
37.
Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M: Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (prorata trial): a multicentre randomised controlled trial. Lancet. 2010, 375: 463-474.
38.
Layios N, Lambermont B, Canivet JL, Morimont P, Preiser JC, Garweg C, Ledoux D, Frippiat F, Piret S, Giot JB, Wiesen P, Meuris C, Massion P, Leonard P, Nys M, Lancellotti P, Chapelle JP, Damas P: Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med. 2012, 40: 2304-2309.
39.
Luyt CE, Combes A, Trouillet JL, Chastre J: Value of the serum procalcitonin level to guide antimicrobial therapy for patients with ventilator-associated pneumonia. Semin Respir Crit Care Med. 2011, 32: 181-187.
40.
Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B: Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther. 2010, 8: 575-587.
41.
Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, Nobre V, Wei L, Bhatnagar N, Bucher HC, Briel M: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012, 9:
42.
Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY: Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006, 34: 1996-2003.
43.
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P: Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013, 13: 426-435.
44.
Quenot JP, Luyt CE, Roche N, Chalumeau M, Charles PE, Claessens YE, Lasocki S, Bedos JP, Pean Y, Philippart F, Ruiz S, Gras-Leguen C, Dupuy AM, Pugin J, Stahl JP, Misset B, Gauzit R, Brun-Buisson C: Role of biomarkers in the management of antibiotic therapy: An expert panel review ii: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy. Ann Intensive Care. 2013, 3: 21-
45.
Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Grarup J, Lundgren JD: Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011, 39: 2048-2058.
46.
Pfister R, Kochanek M, Leygeber T, Brun-Buisson C, Cuquemelle E, Paiva Machado MB, Piacentini E, Hammond NE, Ingram PR, Michels G: Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care. 2014, 18: R44-
47.
Annane D, Maxime V, Faller JP, Mezher C, Clec’h C, Martel P, Gonzales H, Feissel M, Cohen Y, Capellier G, Gharbi M, Nardi O: Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open. 2013, 3: pii: e002186-
48.
Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002, 165: 867-903.
49.
Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C: Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis. 2002, 34: 1047-1054.
50.
Carmeli Y, Troillet N, Eliopoulos GM, Samore MH: Emergence of antibiotic-resistant pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999, 43: 1379-1382.
51.
Luyt CE, Aubry A, Lu Q, Micaelo M, Brechot N, Brossier F, Brisson H, Rouby JJ, Trouillet JL, Combes A, Jarlier V, Chastre J: Imipenem, meropenem, or doripenem to treat patients with pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014, 58: 1372-1380.
52.
Brusselaers N, Labeau S, Vogelaers D, Blot S: Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med. 2013, 39: 365-375.
53.
Michel F, Franceschini B, Berger P, Arnal JM, Gainnier M, Sainty JM, Papazian L: Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest. 2005, 127: 589-597.
54.
Martinez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, Pitart C, Sterzik H, Lopez J, Mensa J: Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010, 54: 3590-3596.
55.
Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, Kollef MH: Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010, 54: 1742-1748.
56.
Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, Choudhury G, Hill AT: Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis. 2011, 53: 107-113.
57.
Garcia-Vidal C, Viasus D, Roset A, Adamuz J, Verdaguer R, Dorca J, Gudiol F, Carratala J: Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin Microbiol Infect. 2011, 17: 1659-1665.
58.
Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, Tarsia P, Mantero M, Blasi F: Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012, 54: 470-478.
59.
Cardoso T, Ribeiro O, Aragao IC, Costa-Pereira A, Sarmento AE: Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study. BMC Infect Dis. 2012, 12: 375-
60.
Jeong BH, Koh WJ, Yoo H, Um SW, Suh GY, Chung MP, Kim H, Kwon OJ, Jeon K: Performances of prognostic scoring systems in patients with healthcare-associated pneumonia. Clin Infect Dis. 2013, 56: 625-632.
61.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y: Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013, 188: 985-995.
62.
Chalmers JD, Rother C, Salih W, Ewig S: Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis. 2014, 58: 330-339.
63.
Park SC, Kim EY, Kang YA, Park MS, Kim YS, Kim SK, Chang J, Jung JY: Validation of a scoring tool to predict drug-resistant pathogens in hospitalised pneumonia patients. Int J Tuberc Lung Dis. 2013, 17: 704-709.
64.
Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, Micek ST, Kollef MH: Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis. 2012, 54: 193-198.
65.
Clark AE, Kaleta EJ, Arora A, Wolk DM: Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clin Microbiol Rev. 2013, 26: 547-603.
66.
Hrabak J, Chudackova E, Walkova R: Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry for detection of antibiotic resistance mechanisms: from research to routine diagnosis. Clin Microbiol Rev. 2013, 26: 103-114.
67.
Clerc O, Prod’hom G, Vogne C, Bizzini A, Calandra T, Greub G: Impact of matrix-assisted laser desorption ionization time-of-flight mass spectrometry on the clinical management of patients with gram-negative bacteremia: a prospective observational study. Clin Infect Dis. 2013, 56: 1101-1107.
68.
Bouza E, Torres MV, Radice C, Cercenado E, de Diego R, Sanchez-Carrillo C, Munoz P: Direct E-test (AB Biodisk) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia. Clin Infect Dis. 2007, 44: 382-387.
69.
Arnold HM, Hollands JM, Skrupky LP, Smith JR, Juang PH, Hampton NB, McCormick S, Reichley RM, Hoban A, Hoffmann J, Micek ST, Kollef MH: Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study. Ann Pharmacother. 2013, 47: 170-180.
70.
Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J: Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013, 56: 236-244.
71.
Shiu J, Wang E, Tejani AM, Wasdell M: Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev. 2013, 3:
72.
Walker MC, Lam WM, Manasco KB: Continuous and extended infusions of beta-lactam antibiotics in the pediatric population. Ann Pharmacother. 2012, 46: 1537-1546.
73.
Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ: Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013, 56: 272-282.
74.
Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA: Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 2012, 2: 37-
75.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL: Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014, 14: 498-509.
76.
Baquero F, Culebras E, Patron C, Perez-Diaz JC, Medrano JC, Vicente MF: Postantibiotic effect of imipenem on gram-positive and gram-negative micro-organisms. J Antimicrob Chemother. 1986, 18: 47-59.
77.
Spivey JM: The postantibiotic effect. Clin Pharm. 1992, 11: 865-875.
78.
Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F: Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010, 14: R126-
79.
Duszynska W, Taccone FS, Hurkacz M, Kowalska-Krochmal B, Wiela-Hojenska A, Kubler A: Therapeutic drug monitoring of amikacin in septic patients. Crit Care. 2013, 17: R165-
80.
Pea F, Viale P, Pavan F, Furlanut M: Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007, 46: 997-1038.
81.
Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R: Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012, 40: 1523-1528.
82.
Trotman RL, Williamson JC, Shoemaker DM, Salzer WL: Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005, 41: 1159-1166.
83.
Lodise TP, Drusano GL: Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Crit Care Clin. 2011, 27: 1-18.
84.
Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F: Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010, 14: R53-
85.
Teo J, Liew Y, Lee W, Kwa AL: Prolonged infusion versus intermittent boluses of beta-lactam antibiotics for treatment of acute infections: a meta-analysis. Int J Antimicrob Agents. 2014, 43: 403-411.
86.
Delattre IK, Musuamba FT, Jacqmin P, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq P: Population pharmacokinetics of four beta-lactams in critically ill septic patients comedicated with amikacin. Clin Biochem. 2012, 45: 780-786.
87.
Grill MF, Maganti RK: Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011, 72: 381-393.
88.
Naeije G, Lorent S, Vincent JL, Legros B: Continuous epileptiform discharges in patients treated with cefepime or meropenem. Arch Neurol. 2011, 68: 1303-1307.
89.
Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R: A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care. 2012, 16: R218-
90.
Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, Boots RJ, Lipman J: Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med. 2014, 42: 520-527.
91.
Luyt CE, Jacob A, Combes A, Nieszkowszka A, Fernandez C, Trouillet JL, Corkery K, Farinotti R, Chastre J: Nktr-061 (inhaled amikacin) achieves high epithelial lining fluid concentrations in gram-negative pneumonia in intubated and mechanically ventilated patients [abstract]. Am J Respir Crit Care Med. 2007, 175: A328-
92.
Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, Garcia MS: Bay41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med. 2012, 38: 263-271.
93.
Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, Varela M, Tempone AK, O’Riordan T, Daroowalla F, Richman P: Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med. 2008, 36: 2008-2013.
94.
Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J: Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr Opin Infect Dis. 2009, 22: 154-158.
95.
Luyt CE, Eldon MA, Stass H, Gribben D, Corkery K, Chastre J: Pharmacokinetics and tolerability of amikacin administered as bay41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv. 2011, 24: 183-190.
96.
Palmer LB, Smaldone GC: Reduction of bacterial resistance with inhaled antibiotics in the ICU. Am J Respir Crit Care Med. 2014, 189: 1225-1233.
97.
Stevens RM, Teres D, Skillman JJ, Feingold DS: Pneumonia in an intensive care unit. A 30-month experience. Arch Intern Med. 1974, 134: 106-111.
98.
Buelow E, Gonzalez TB, Versluis D, Oostdijk EA, Ogilvie LA, van Mourik MS, Oosterink E, van Passel MW, Smidt H, D’Andrea MM, de Been M, Jones BV, Willems RJ, Bonten MJ, van Schaik W: Effects of selective digestive decontamination (SDD) on the gut resistome. J Antimicrob Chemother. 2014, -[Epub ahead of print]
99.
Oostdijk EA, Smits L, de Smet AM, Leverstein-van Hall MA, Kesecioglu J, Bonten MJ: Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. Intensive Care Med. 2013, 39: 653-660.
100.
Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000, 162: 505-511.
101.
Torres A, Ewig S: Diagnosing ventilator-associated pneumonia. N Engl J Med. 2004, 350: 433-435.
102.
Baselski VS, Wunderink RG: Bronchoscopic diagnosis of pneumonia. Clin Microbiol Rev. 1994, 7: 533-558.
103.
Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, Tenaillon A: Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med. 2000, 132: 621-630.
104.
Charbonneau P, Parienti JJ, Thibon P, Ramakers M, Daubin C, du Cheyron D, Lebouvier G, Le Coutour X, Leclercq R: Fluoroquinolone use and methicillin-resistant staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis. 2006, 42: 778-784.
105.
Nseir S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M, Onimus T, Saulnier F, Mathieu D, Durocher A: First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med. 2005, 33: 283-289.
106.
Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ: Escmid* guideline for the diagnosis and management of candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012, 18: 19-37.
107.
Rello J, Vidaur L, Sandiumenge A, Rodriguez A, Gualis B, Boque C, Diaz E: De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004, 32: 2183-2190.
108.
Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Manolas K: De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med. 2007, 33: 1533-1540.
109.
Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N: Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother. 2011, 66: 1223-1230.
110.
Kim JW, Chung J, Choi SH, Jang HJ, Hong SB, Lim CM, Koh Y: Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial. Crit Care. 2012, 16: R28-
111.
Silva BN, Andriolo RB, Atallah AN, Salomao R: De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev. 2013, 3:
112.
Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME: Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis. 2005, 41: 149-158.
113.
Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Grundling M, Moerer O, Riessen R, Seibel A, Ragaller M, Buchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T: Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA. 2012, 307: 2390-2399.
114.
Chamot E, Boffi El Amari E, Rohner P, Van Delden C: Effectiveness of combination antimicrobial therapy for pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2003, 47: 2756-2764.
115.
Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken I, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto Infection Program. Antimicrob Agents Chemother. 1996, 40: 1108-1115.
116.
Dupont H, Carbon C, Carlet J: Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial, The Severe Generalized Peritonitis Study Group. Antimicrob Agents Chemother. 2000, 44: 2028-2033.
117.
Falagas ME, Matthaiou DK, Bliziotis IA: The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother. 2006, 57: 639-647.
118.
Furno P, Bucaneve G, Del Favero A: Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis. 2002, 2: 231-242.
119.
Heyland DK, Dodek P, Muscedere J, Day A, Cook D: Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008, 36: 737-744.
120.
Kumar A, Safdar N, Kethireddy S, Chateau D: A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med. 2010, 38: 1651-1664.
121.
Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L: Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2006, 1:
122.
Tamma PD, Cosgrove SE, Maragakis LL: Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev. 2012, 25: 450-470.
123.
Marcus R, Paul M, Elphick H, Leibovici L: Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents. 2011, 37: 491-503.
124.
Pena C, Suarez C, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodriguez-Bano J, Rodriguez F, Tubau F, Oliver A, Martinez-Martinez L: Effect of adequate single-drug vs combination antimicrobial therapy on mortality in pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis. 2013, 57: 208-216.
125.
Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ: Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005, 26: 1138-1180.
126.
Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O’Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG: Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the Infectious Diseases Society of America. Clin Infect Dis. 2010, 50: 133-164.
127.
Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J: Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Crit Care Med. 2007, 35: 146-154.
128.
Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ: Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med. 2001, 163: 1371-1375.
129.
Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, Palizas F, Menga G, Rios F, Apezteguia C: Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med. 2003, 31: 676-682.
130.
Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003, 290: 2588-2598.
131.
Micek ST, Ward S, Fraser VJ, Kollef MH: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest. 2004, 125: 1791-1799.
132.
Hedrick TL, McElearney ST, Smith RL, Evans HL, Pruett TL, Sawyer RG: Duration of antibiotic therapy for ventilator-associated pneumonia caused by non-fermentative gram-negative bacilli. Surg Infect (Larchmt). 2007, 8: 589-598.
133.
Capellier G, Mockly H, Charpentier C, Annane D, Blasco G, Desmettre T, Roch A, Faisy C, Cousson J, Limat S, Mercier M, Papazian L: Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. PLoS One. 2012, 7: e41290-
134.
Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK: Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest. 2013, 144: 1759-1767.
135.
Pugh R, Grant C, Cooke RP, Dempsey G: Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2011, 10:
136.
Eliakim-Raz N, Yahav D, Paul M, Leibovici L: Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection - 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2013, 68: 2183-2191.
137.
Havey TC, Fowler RA, Daneman N: Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care. 2011, 15: R267-
138.
Kyriakidou KG, Rafailidis P, Matthaiou DK, Athanasiou S, Falagas ME: Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials. Clin Ther. 2008, 30: 1859-1868.
139.
Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008, 177: 498-505.
140.
Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Luyt CE, Chastre J, Tubach F, Kristoffersen KB, Wei L, Burkhardt O, Welte T, Schroeder S, Nobre V, Tamm M, Bhatnagar N, Bucher HC, Mueller B: Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012, 55: 651-662.
141.
Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A: Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2010, 38: 2229-2241.
142.
Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G: An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med. 2012, 38: 940-949.
143.
Prkno A, Wacker C, Brunkhorst FM, Schlattmann P: Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock - a systematic review and meta-analysis. Crit Care. 2013, 17: R291-
144.
Cotta MO, Roberts JA, Tabah A, Lipman J, Vogelaers D, Blot S: Antimicrobial stewardship of beta-lactams in intensive care units. Expert Rev Anti Infect Ther. 2014, 12: 581-595.
145.
Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007, 44: 159-177.
146.
Lawrence KL, Kollef MH: Antimicrobial stewardship in the intensive care unit: advances and obstacles. Am J Respir Crit Care Med. 2009, 179: 434-438.
147.
Davey P, Brown E, Fenelon L, Finch R, Gould I, Hartman G, Holmes A, Ramsay C, Taylor E, Wilcox M, Wiffen P: Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2005, 4:
148.
Gomes Silva BN, Andriolo RB, Atallah AN, Salomao R: De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev. 2010, 12:
149.
Weiss CH, Dibardino D, Rho J, Sung N, Collander B, Wunderink RG: A clinical trial comparing physician prompting with an unprompted automated electronic checklist to reduce empirical antibiotic utilization. Crit Care Med. 2013, 41: 2563-2569.
150.
Weiss CH, Moazed F, McEvoy CA, Singer BD, Szleifer I, Amaral LA, Kwasny M, Watts CM, Persell SD, Baker DW, Sznajder JI, Wunderink RG: Prompting physicians to address a daily checklist and process of care and clinical outcomes: a single-site study. Am J Respir Crit Care Med. 2011, 184: 680-686.
151.
Pestotnik SL, Classen DC, Evans RS, Burke JP: Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med. 1996, 124: 884-890.
152.
Belletti D, Zacker C, Mullins CD: Perspectives on electronic medical records adoption: electronic medical records (EMR) in outcomes research. Patient Relat Outcome Meas. 2010, 1: 29-37.
153.
Kullar R, Goff DA, Schulz LT, Fox BC, Rose WE: The ‘Epic’ challenge of optimizing antimicrobial stewardship: the role of electronic medical records and technology. Clin Infect Dis. 2013, 57: 1005-1013.
154.
Leibovici L, Gitelman V, Yehezkelli Y, Poznanski O, Milo G, Paul M, Ein-Dor P: Improving empirical antibiotic treatment: prospective, nonintervention testing of a decision support system. J Intern Med. 1997, 242: 395-400.
155.
Bailey TC, Ritchie DJ, McMullin ST, Kahn M, Reichley RM, Casabar E, Shannon W, Dunagan WC: A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy. 1997, 17: 277-281.
156.
Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001, 29: 1109-1115.
157.
Rimawi RH, Mazer MA, Siraj DS, Gooch M, Cook PP: Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. Crit Care Med. 2013, 41: 2099-2107.
Metadata
Title
Antibiotic stewardship in the intensive care unit
Authors
Charles-Edouard Luyt
Nicolas Bréchot
Jean-Louis Trouillet
Jean Chastre
Publication date
01-10-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 5/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-014-0480-6

Other articles of this Issue 5/2014

Critical Care 5/2014 Go to the issue

Research

Early activation of pro-fibrotic WNT5A in sepsis-induced acute lung injury

Letter

Delivery of fetus death with misoprostol in a pregnant woman with H7N9 avian influenza A virus pneumonia and ARDS

Research

Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation

Research

Detecting acute distress and risk of future psychological morbidity in critically ill patients: validation of the intensive care psychological assessment tool

Research

Hospital mortality of adults admitted to Intensive Care Units in hospitals with and without Intermediate Care Units: a multicentre European cohort study

Research

Seventy-two hours of mild hypothermia after cardiac arrest is associated with a lowered inflammatory response during rewarming in a prospective observational study